Abcam, ab305705, APC Anti-AGL antibody [EPR8880]

Size: 100µL
Rabbit Recombinant Monoclonal AGL/Alpha-glucosidase antibody - conjugated to APC.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR8880,
Isotype:IgG,
Conjugation:APC,
Excitation/Emission:Ex: 650nm, Em: 660nm,
Carrier free:No,
Applications:Antibody Labelling, Target Binding AffinitySee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.

Product details:
conjugated primary antibody
is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the
Lightning-Link® conjugation technology
, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Alpha-glucosidase also known as AGL is an enzyme that breaks down carbohydrates by hydrolyzing alpha-14 glycosidic bonds in glycogen converting them into glucose molecules. This enzyme is important for the body's ability to derive glucose from stored glycogen a necessary process for maintaining energy levels. AGL is predominantly expressed in liver tissue where it plays an important role in glycogen metabolism. The AGL enzyme has an approximate mass of around 104 kDa. Additionally AGL can be referred to as alpha-16-glucosidase due to its specific hydrolytic capabilities on branching points in glycogen.
Biological function summary
AGL functions as part of the glycogen debranching enzyme complex which is important for glycogen catabolism. It cooperates with other enzymes to effectively mobilize glucose from glycogen stores. AGL's debranching activity ensures the smooth continuation of glycogenolysis providing glucose to meet energy demands during fasting or intense physical activity. This highlights the enzyme's importance in glucose homeostasis and metabolic processes that require rapid energy availability.
Pathways
AGL participates in the glycogenolysis and gluconeogenesis pathways. It partners with phosphorylase to release glucose-1-phosphate from glycogen ensuring energy supply during fasting conditions. The glycogenolysis pathway relies significantly on AGL for breaking down glycogen's branched structures while glucose-6-phosphatase assists in converting glucose-6-phosphate into free glucose. AGL's role in these pathways illustrates its importance in energy metabolism and glucose regulation.
AGL's dysfunction is linked to glycogen storage disease type III known as Cori disease. This genetic disorder results from mutations in the AGL gene causing a build-up of abnormally structured glycogen in the liver and muscles leading to symptoms such as hepatomegaly muscular weakness and hypoglycemia. AGL along with other enzymes involved in glycogen metabolism like phosphorylase kinase is a target for therapeutic interventions aimed at managing such glycogen storage diseases.